Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Current Deferred Revenue (2018 - 2020)

Tvardi Therapeutics' Current Deferred Revenue history spans 6 years, with the latest figure at $511000.0 for Q3 2020.

  • On a quarterly basis, Current Deferred Revenue fell 98.09% to $511000.0 in Q3 2020 year-over-year; TTM through Sep 2020 was $511000.0, a 98.09% decrease, with the full-year FY2019 number at $22.3 million, down 17.01% from a year prior.
  • Current Deferred Revenue hit $511000.0 in Q3 2020 for Tvardi Therapeutics, down from $9.8 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for TVRD hit a ceiling of $29.2 million in Q3 2018 and a floor of $511000.0 in Q3 2020.
  • Historically, Current Deferred Revenue has averaged $20.7 million across 3 years, with a median of $24.4 million in 2018.
  • Biggest five-year swings in Current Deferred Revenue: grew 18.87% in 2019 and later tumbled 98.09% in 2020.
  • Tracing TVRD's Current Deferred Revenue over 3 years: stood at $26.8 million in 2018, then dropped by 17.01% to $22.3 million in 2019, then plummeted by 97.7% to $511000.0 in 2020.
  • Business Quant data shows Current Deferred Revenue for TVRD at $511000.0 in Q3 2020, $9.8 million in Q2 2020, and $14.2 million in Q1 2020.